Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1871526520666201013160803 http://scihub22266oqcxt.onion/10.2174/1871526520666201013160803 33050869!ä!33050869 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Infect+Disord+Drug+Targets 2021 ; 21 (5): e270421186842 Nephropedia Template TP {{tp|p=33050869|t=2021. COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail |pdf=|usr=}}{{33050869}} gab.com Text COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail JO: Infect Disord Drug Targets http://www.kidney.de/pget.php?&tw=1&pmid=33050869 #FOAvip The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug. Twit Text FOAVip COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail ????Infect Disord Drug Targets http://www.kidney.de/pget.php?&tw=1&pmid=33050869 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33050869 #FOAvip English Wikipedia <ref>{{Cite pmid|33050869}}</ref> COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail #MMPMID33050869 Pal R; Bhasin MK; Bhadada SK Infect Disord Drug Targets 2021[]; 21 (5): e270421186842 PMID33050869show ga The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, HCQ is being used for treatment and prophylaxis in patients with COVID-19. HCQ is also used as an anti-diabetic drug and has been approved in India as an adjunct to diet and exercise to improve glycemic control of patients with Type 2 Diabetes Mellitus (T2DM) on metformin and sulfonylurea combination in Type 2 Diabetes Mellitus (T2DM). Thus, although indiscriminate use of HCQ is fraught with danger, HCQ can be considered as a third-line add on anti-diabetic agent in people with T2DM amid the ongoing pandemic after having ruled out the contraindications to the use of this drug. |*COVID-19[MESH] |*Diabetes Mellitus, Type 2/drug therapy[MESH] |Humans[MESH] |India[MESH] |Pandemics[MESH]COVID-19 and Type 2 Diabetes Mellitus: HCQ may be the Holy Grail (epmc).pdf DeepDyve Pubget Overpricing